Lumos Diagnostics Holdings Limited announced that Health Canada has granted Interim Order authorization for the Lumos CoviDxTM SARS-CoV-2 Rapid Antigen Test. The CoviDx test gives qualified healthcare providers qualitative, easy-to-interpret results within 15-20 minutes in cases of suspected COVID-19 and when performing serial testing of asymptomatic patients. CoviDx is authorized by Health Canada for use by qualified healthcare professionals in evaluating symptomatic patients, and for serial testing of patients without symptoms. The CoviDx test is a stand- alone POC test that uses individual pre-filled extraction reagent vials to make it easy to administer in any patient care setting ? without any additional instruments or equipment. The test is compatible with both nasopharyngeal and the less invasive nasal swab sample collection and provides a simple "yes/no" result. With Health Canada's Interim Order authorization, CoviDx is available to qualified healthcare providers across the country through Lumos' distribution partners.